GlassScriptPhysician profile
Evelyn Lopez-Brignoni
NPI 1306060256
$11,148.01
in general payments reported to CMS, 2019-2025
30 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $725 · 2021: $1,749 · 2022: $1,190 · 2023: $1,916 · 2024: $2,067 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,922.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,507.30 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $1,088.12 | 2019-2022 | |
| Axsome Therapeutics, INC. | $860.28 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $557.93 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $545.05 | 2020-2025 | Uzedy, Austedo, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $470.99 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $461.17 | 2019-2025 | Trintellix |
| Pfizer INC. | $441.76 | 2019 | |
| Allergan, INC. | $434.20 | 2019-2020 | |
| Corium, LLC | $346.89 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $341.56 | 2021-2025 | Caplyta |
| Lundbeck LLC | $260.76 | 2020-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $260.68 | 2021-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Almatica Pharma LLC | $163.35 | 2024-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $116.50 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $43.42 | 2023-2025 | Dyanavel Xr |
| Shire North American Group INC | $43.19 | 2019 | |
| Ironshore Pharmaceuticals INC. | $40.60 | 2019-2024 | |
| Neuronetics, INC. | $37.13 | 2025 | Neurostar Tms Therapy System |
| Bausch Health US, LLC | $36.93 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $32.75 | 2025 | Hetlioz, Fanapt |
| Noven Therapeutics, LLC | $21.35 | 2020 | |
| Tempus Ai, INC | $19.21 | 2024 | |
| Noven Pharmaceuticals, INC. | $16.89 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Lopez-Brignoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.